Biomea Fusion Inc (BMEA NASDAQ) stock market data APIs
$2.1821
-0.13(-6%)
as of May 2, 2025
Biomea Fusion Inc Financial Data Overview
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Prev. Close
2.1821
Open
2.0496
High
2.2393
Low
2.0496
52 wk Range
1.53-13.43
Market Cap
78 902 K
Shares Outstanding
37 572 K
EPS
-0.808
Beta
-0.088
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biomea Fusion Inc data using free add-ons & libraries
Get Biomea Fusion Inc Fundamental Data
Biomea Fusion Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -142 322 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-01
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biomea Fusion Inc News
New
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announ...
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated...
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE...
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovameni...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
